A current review of folate receptor alpha as a potential tumor target in non-small-cell lung cancer.

Abstract

Lung cancer remains the leading common cause of cancer-related death, with non-small-cell lung cancer (NSCLC) accounting for 80% of all cases. To date, platinum-based doublet chemotherapy is the cornerstone of first-line therapy. However, these agents have limited use in patients who have relapsed and have metastatic disease. Therefore, novel strategies are required to improve the clinical outcome. Folate receptor alpha (FRA) is overexpressed in the majority of NSCLC, particularly in lung adenocarcinomas. FRA is largely absent from normal tissue, making it an attractive therapeutic target. In this review, we discuss FRA expression in NSCLC, conjugated FRA agents, monoclonal antibody, and FRA-specific T-cell-based therapeutic strategies aiming to improve the cure rate of FRA-expressing NSCLC.

• Authors: Huan Shi, Jun Guo, Changzheng Li, Zhehai Wang
• Journal: Drug design, development and therapy (Drug Des Devel Ther) Vol. 9 Pg. 4989-96 ( 2015) ISSN: 1177-8881 [Electronic] New Zealand
• PMID: 26357465 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Antibodies, Monoclonal
• Antineoplastic Agents
• FOLR1 protein, human
• Folate Receptor 1

Topics

• Animals
• Antibodies, Monoclonal (therapeutic use)
• Antineoplastic Agents (therapeutic use)
• Carcinoma, Non-Small-Cell Lung (immunology, metabolism, pathology, therapy)
• Folate Receptor 1 (antagonists & inhibitors, immunology, metabolism)
• Humans
• Immunotherapy, Adoptive (methods)
• Lung Neoplasms (immunology, metabolism, pathology, therapy)
• Molecular Targeted Therapy
• Signal Transduction (drug effects)
• T-Lymphocytes (immunology, transplantation)